Get the Stockscreener App
9.63
3.60%
-0.36
Syndax Pharmaceuticals Inc stock is traded at $9.63, with a volume of 1.27M.
It is down -3.60% in the last 24 hours and up +8.20% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$9.99
Open:
$10
24h Volume:
1.27M
Relative Volume:
0.59
Market Cap:
$828.64M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-3.2534
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+1.80%
1M Performance:
+8.20%
6M Performance:
-32.42%
1Y Performance:
-60.90%
1-Day Range:
$9.55
$10.00
1-Week Range:
$9.38
$10.50
52-Week Range:
$8.58
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
9.63 | 859.61M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Is Syndax Pharmaceuticals Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia
What analysts say about Syndax Pharmaceuticals Inc. stockRapid market gains - PrintWeekIndia
Should I buy Syndax Pharmaceuticals Inc. stock before earningsGame-changing capital returns - jammulinksnews.com
What drives Syndax Pharmaceuticals Inc. stock priceDynamic capital growth - PrintWeekIndia
Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613 - TipRanks
Syndax Pharmaceuticals Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat
Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves! - TipRanks
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc. stock a good hedge against inflationFree Insider Trading Tips - Newser
Will Syndax Pharmaceuticals Inc. stock benefit from interest rate changesBreakout Confirmation Tool - Newser
(SNDX) Trading Advice - news.stocktradersdaily.com
UBS Group Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% on Analyst Downgrade - Defense World
Syndax CFO and CEO sell shares at $9.29/share on July 16, 2025. - AInvest
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML - MSN
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst Downgrade - MarketBeat
What makes Syndax Pharmaceuticals Inc. stock price move sharplyPro Trader Stock Focus - Newser
UBS Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $35 - GuruFocus
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):